In a patient with depression on fluoxetine 20 mg PO daily who reports modest improvement, decreased motivation, missed doses, disrupted sleep, minimal anxiety, and a recent episode of passive suicidal ideation, how should the fluoxetine be managed and what augmentation strategy should be considered?

Medication Management Strategy

Address medication adherence first, then optimize the fluoxetine dose to 40-60 mg daily given modest response at 20 mg, while implementing close monitoring for suicidal ideation and considering augmentation with bupropion if inadequate response persists after 3-4 weeks at the higher dose.

Immediate Priorities

1. Adherence Assessment and Intervention

The patient missed two doses last week, which directly undermines treatment efficacy. Parental oversight of medication regimens is of paramount importance in adolescents 1. Before making any dose changes:

• Implement a structured medication administration system (pill organizer, phone reminders, parental supervision)
• Address barriers to adherence (side effects, motivation, access)
• Consider that fluoxetine's long half-life (4-6 days for fluoxetine, 4-16 days for active metabolite norfluoxetine) provides some protection against missed doses 2, but consistent dosing is still essential

2. Dose Optimization

The current 20 mg dose is insufficient given only modest improvement. The FDA label and clinical trials support doses up to 60-80 mg daily for depression 2. For adolescents specifically:

• Increase fluoxetine to 40 mg daily after confirming adherence 2
• If inadequate response after 3-4 weeks at 40 mg (fluoxetine requires 3-4 week intervals for dose adjustments due to its long half-life 1), increase to 60 mg daily
• Maximum dose should not exceed 80 mg/day 2

The rationale: Studies show 20 mg/day is sufficient for most cases, but doses above 20 mg may be needed when insufficient clinical improvement is observed 2. The full therapeutic effect may be delayed until 4 weeks of treatment or longer 2.

Addressing Specific Symptoms

Decreased Motivation and Spending Days in Bed

These residual symptoms of anhedonia and anergia are functionally impairing and often persist despite mood improvement 3. If these symptoms don't improve with fluoxetine dose optimization after 3-4 weeks:

Consider augmentation with bupropion 150 mg daily (can increase to 300 mg):

• Bupropion has significantly lower rates of sexual dysfunction than fluoxetine 4
• It tends to be activating and can reduce apathy 5
• Low-quality evidence shows augmenting citalopram with bupropion decreases depression severity more than augmentation with buspirone 6
• Bupropion may be associated with increased seizure risk at higher doses, so maximum dose should not exceed 300 mg daily in divided doses 4

Disrupted Sleep Schedule

While sleep quantity is adequate, the disrupted schedule may perpetuate depression symptoms. Insomnia severity is an independent indicator of suicidal ideation even when accounting for core depression symptoms 7. Address through:

• Sleep hygiene counseling
• Consider timing fluoxetine dose to morning to minimize sleep disruption 2
• If insomnia worsens with dose increase, this is a known early side effect that often resolves 1

Suicidal Ideation Management

The passive suicidal ideation episode requires heightened vigilance but doesn't necessarily mandate medication discontinuation. The risk of not prescribing or undertreating depression is significantly higher than the risk of continuing treatment 8.

Monitoring Protocol

Close monitoring is essential, especially in the first months of treatment and following dosage adjustments 1, 8:

• Weekly contact (in-person or phone) for the next 4 weeks after any dose change
• Systematic assessment using Columbia Suicide Severity Rating Scale at each contact
• Direct questioning about suicidal ideation (asking directly is more reliable than waiting for spontaneous reports) 8
• Monitor for behavioral activation/agitation, which is associated with emergence of suicidal ideation 9

Evidence on SSRIs and Suicidality

The black-box warning context is important but shouldn't prevent appropriate treatment:

• Pooled absolute rates for suicidal ideation: 1% with antidepressants vs 0.2% with placebo (risk difference 0.7%, number needed to harm = 143) 1
• Number needed to treat for response = 3 1
• Reanalysis of fluoxetine studies in youth showed 46.6% remission with fluoxetine vs 16.5% with placebo over 6 weeks 8
• No overall greater rate of suicidal thoughts/behaviors in fluoxetine treatment groups vs placebo in youth 8
• Most youth suicide victims (98.4%) did not have recent SSRI exposure, suggesting undertreating depression is the greater risk 8

When to Consider Hospitalization

Hospitalization would be indicated if the patient develops:

• Active suicidal ideation with plan, intent, or method
• Inability to contract for safety
• Acute behavioral changes suggesting imminent risk
• Severe functional deterioration preventing self-care

Psychotherapy Integration

The psychotherapy referral was appropriate. Combination treatment (CBT and an SSRI) is suggested preferentially over monotherapy for adolescents with depression 1. Ensure the referral is actively pursued and treatment initiated, as therapy addresses functional impairment and provides additional suicide prevention strategies.

Timeline and Reassessment

• Week 1-2: Confirm adherence, increase to 40 mg, weekly monitoring
• Week 4-6: Assess response; if inadequate, increase to 60 mg
• Week 8-10: If persistent anhedonia/anergia despite dose optimization, add bupropion
• Week 12: Full reassessment of response

The full therapeutic effect may be delayed until 4 weeks of treatment or longer 2, so patience with dose adjustments is essential while maintaining close safety monitoring.